



## MannKind to Present at Upcoming Conferences

09/07/10

MannKind to Present at Upcoming Conferences

VALENCIA, Calif., Sep 07, 2010 (BUSINESS WIRE) -- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at upcoming conferences.

- Morgan Stanley Global Healthcare Conference on September 13, 2010 at 1:35 PM EDT at the Grand Hyatt in New York, NY
- Baird Healthcare Conference on September 14, 2010 at 1:45 PM EDT at the St. Regis Hotel in New York, NY
- Rodman & Renshaw Annual Global Investment Conference on September 14, 2010 at 2:00 PM EDT at the New York Palace Hotel in New York, NY
- Imperial Capital Annual Global Opportunities Conference on September 15, 2010 at 8:35 AM EDT at the Grand Hyatt in New York, NY
- UBS Global Life Sciences Conference on September 21, 2010 at 3:00 PM EDT at the Grand Hyatt in New York, NY
- JMP Securities Healthcare Conference on September 28, 2010 at 9:30 AM EDT at the New York Palace Hotel in New York, NY

Interested parties can access a link to the live webcast of the presentations from the News & Media section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

### About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFREZZA and MKC253. MKC253 is currently in phase 1 clinical trials. In March 2009, MannKind submitted a NDA to the FDA requesting approval of AFREZZA for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia. In March 2010, MannKind received a Complete Response letter to this NDA from the FDA, requesting additional information. In July 2010, the FDA accepted MannKind's reply to the Complete Response letter and set a PDUFA action date of December 29, 2010. Other products in MannKind's pipeline include the cancer immunotherapy products MKC1106-PP and MKC1106-MT, which are currently in phase 1 clinical trials. MannKind maintains a website at <http://www.mannkindcorp.com> to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

SOURCE: MannKind Corporation

MannKind Corporation  
Matthew J. Pfeffer  
Corporate Vice President and  
Chief Financial Officer  
661-775-5300  
[mpfeffer@mannkindcorp.com](mailto:mpfeffer@mannkindcorp.com)